Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: Clin Cancer Res. 2018 Mar 7;24(11):2616–2630. doi: 10.1158/1078-0432.CCR-17-1207

Figure 3. TAZ suppression promotes myogenic differentiation, and enriches the G2/M population.

Figure 3.

(A, B) Rh28 and Rh30 cells stably expressing TAZ shRNAs and cultured in differentiation-inducing conditions display morphologic elongation as well as increased staining for MF20 (myosin heavy chain) expression, (C, D) increased MF20 expression as measured by immunoblot, and (E, F) increased myogenic marker expression as measured by qRT-PCR. Scale bars, 100μm. (G, H) Rh28 and Rh30 cells stably expressing TAZ shRNAs show an increase in the G2/M phase of the cell cycle as measured by flow cytometry of DNA content. Bars represent the average and SE of each group. N=3 (Rh28s), N=2 (Rh30s). (I) As measured by immunoblot for M-phase specific phosphorylation of histone H3, TAZ suppression in Rh30 cells leads to an accumulation of cells in M phase. Actin used as loading control. NT, non-targeting scrambled control vector.